Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis-Reference-Cited by-同舟云学术

Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Published:2021-01-25 Issue:12 Volume:66 Page:4475-4484
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Matsumoto Takaaki,Okuwaki Kosuke^ORCID,Imaizumi Hiroshi,Kida Mitsuhiro,Iwai Tomohisa,Yamauchi Hiroshi,Kaneko Toru,Hasegawa Rikiya,Masutani Hironori,Tadehara Masayoshi,Adachi Kai,Watanabe Masafumi,Kurosu Takahiro,Tamaki Akihiro,Kikuchi Hidehiko,Ohno Takashi,Koizumi Wasaburo

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

https://link.springer.com/content/pdf/10.1007/s10620-020-06782-6.pdf

Reference30 articles.

1. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001;96:417–423.

2. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54:425–434.

3. Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol. 2006;101:139–147.

4. Zheng M, Chen Y, Yang X, Li J, Zhang Y, Zeng Q. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2007;7:6.

5. Rudin D, Kiss A, Wetz RV, Sottile VM. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol. 2007;22:977–983.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERCP後膵炎ガイドライン2023;Suizo;2024-04-30

2. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure;World Journal of Clinical Cases;2024-01-06

3. Update in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis;Annals of Gastroenterology;2024

4. Nafamostat Reduces the Incidence of post‐ERCP Pancreatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials;Clinical Pharmacology & Therapeutics;2023-12-29

5. Efficacy of nafamostat mesylate in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis of randomized controlled trials;Scientific Reports;2023-12-27